IVT and Solvo Announces Distribution Agreement For Solvo’s Products
News Oct 25, 2005
In Vitro Technologies, Inc. (IVT) and Solvo Biotechnologies Inc. have announced that they have formed a strategic partnership to distribute Solvo’s in vitro ABC Membrane Transporter Assay Product Line in the US and Canada.
Continuing with IVT’s commitment to bring an extensive line of solutions for drug discovery and development research, IVT and Solvo have collaborated to leverage IVT’s strength in the marketplace and Solvo’s innovative Membrane Transporter products.
“We are very excited about this partnership with Solvo and firmly believe that it will deliver additional value to pharmaceutical research customers in North America,” said Dr. Paul Silber, President and CEO of IVT.
“By making the products available from with in the United States, we are making the purchase process efficient and cost-effective coupled with increased ability to provide technical support.”
“By now, it is common knowledge among researchers that ABC transporters play a key role in the function of the blood-brain barrier (BBB), blood-CSF barrier, blood-testis barrier, intestinal epithelia (absorption), airway epithelia, liver epithelia and the kidney epithelia,” explained Gábor Heltovics, Solvo’s Business Development Director.
“Solvo’s leading in vitro assay systems are designed to detect interaction of test compounds with a wide array of ABC Transporter proteins found at these vital pharmacological barriers.”
“Our products are widely used for in vitro ADME/Tox, DMPK, oncology drug research and multi-drug resistant (MDR) modulating agent discovery.”
“We welcome the opportunity to work with In Vitro Technologies, Inc. as an ideal partner to further expand the usage of our products”.
A new experimental system has been designed that can rapidly assess the pathogenic effects of a drug on a baby's developing brain. The system uses embryonic stem cells reprogrammed into neurons, and offers a powerful tool for probing genetic and molecular underpinnings of drug-induced neurodevelopmental disorders.READ MORE
An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.READ MORE